Lucira Health Dividends and Buybacks

Dividend criteria checks 0/6

Lucira Health does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-38,984.7%

Buyback Yield

Total Shareholder Yield	-38,984.7%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Lucira Health reports early data for point of care chlamydia and gonorrhea assays

Sep 29

Lucira COVID & Flu test gets emergency use authorization from Health Canada

Aug 11

Lucira Health Sees Strong Revenue Growth But Needs More Cash

Mar 10

Analysts' Revenue Estimates For Lucira Health, Inc. (NASDAQ:LHDX) Are Surging Higher

Nov 25

Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?

Jun 29

Lucira Health appoints medtech veteran Kevin Collins as CRO

May 28

Health Canada issues 'authorization with conditions' for Lucira's COVID-19 test kit

Apr 26

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LHDX.Q's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LHDX.Q's dividend payments have been increasing.

Dividend Yield vs Market

Lucira Health Dividend Yield vs Market

How does LHDX.Q dividend yield compare to the market?
Segment	Dividend Yield
Company (LHDX.Q)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.3%
Industry Average (Medical Equipment)	1.6%
Analyst forecast (LHDX.Q) (up to 3 years)	0%

Notable Dividend: Unable to evaluate LHDX.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LHDX.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LHDX.Q's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LHDX.Q has not reported any payouts.

Lucira Health Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Lucira Health, Inc. Files Form 15

Lucira Health, Inc. Announces Erik T. Engelson, Chief Executive Officer Resigned from the Position

Lucira Health, Inc. announced delayed 10-Q filing

Lucira Health, Inc. announced delayed 10-Q filing

Lucira Health, Inc. Appoints Richard Narido as Chief Financial Officer

Lucira Health Receives A Notification Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price

Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic with First and Only Combination Covid-19 and Flu OTC Molecular Self-Test

Lucira Health, Inc. Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care

Lucira Health, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Lucira Health, Inc. Announces Board Changes

Lucira Health, Inc. Reports Pilot Study Interim Results for Chlamydia and Gonorrhea Assays

Consensus EPS estimates fall by 1,050%

Lucira Health reports early data for point of care chlamydia and gonorrhea assays

Lucira Health, Inc. Announces Board Changes

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$5.50

High number of new directors

Health Canada Grants Authorization Under Interim Order for the Emergency Use and Commercialization of the First and Only At-Home Test for Covid & Flu of Lucira Health, Inc

Lucira COVID & Flu test gets emergency use authorization from Health Canada

Lucira Health, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Lucira Health, Inc. Provides Revenue Guidance for the Second Quarter and Third Quarter of 2022

Lucira Health, Inc. Withdraws Previously Announced 2022 Annual Revenue Guidance

Lucira Receives CE Mark for Both Covid-19 & Flu and Covid-19 Molecular Tests

Price target decreased to US$7.00

High number of new directors

Lucira Health, Inc., Annual General Meeting, Jun 01, 2022

Lucira Health, Inc. Covid-19 & Flu At-Home Molecular Test Shows Positive Clinical Study Results

President recently bought US$90k worth of stock

Price target decreased to US$7.00

Lucira Health Sees Strong Revenue Growth But Needs More Cash

Lucira Health, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Lucira Health, Inc. Announces Lucira™ Check-It PCR-Quality

Forecast to breakeven in 2022

Lucira Health, Inc. Announces Its Lucira Check-It (OTC) and All-In-One (Rx) Test Kits Can Detect Omicron (B.1.1.529), A SARS CoV-2 Variant of Concern

Analysts' Revenue Estimates For Lucira Health, Inc. (NASDAQ:LHDX) Are Surging Higher

Executive Vice President of Commercialization, Regulatory, Clinical & Business Development Kelly Lewis Brezoczky has left the company

Chief Operating Officer Hansgregory Hartmann has left the company

Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?

Lucira Health, Inc.(NasdaqGS:LHDX) dropped from Russell 3000E Growth Index

Lucira Health appoints medtech veteran Kevin Collins as CRO

Consensus revenue estimates fall to US$51.5m

Lucira Health, Inc. Announces Lucira Check it Covid-19 Self-Test Available on Amazon

Consensus forecasts updated

Health Canada Authorizes First COVID-19 Test for Self-Testing At Home by Lucira Health, Inc

Health Canada issues 'authorization with conditions' for Lucira's COVID-19 test kit

Lucira Health, Inc. Provides Revenue Guidance for the Three Months Ended March 31, 2021

U.S. Physicians Can Now Order Lucira Health Self-Administered, Lab Quality, Covid-19 Molecular Test for Home or Office

Lucira Health, Inc. has completed an IPO in the amount of $153 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies